Pembrolizumab

点击蓝字 关注我们 本 期 看 点 历史总是惊人的相似，去年也是ASCO会议期间，summit迎来市场的重挫：久等不至的BD，Summit第二季度财报深度分析、PFS优异，OS未达标，Summit大跌26%：依沃西单抗能否突围FDA审评红线？ 在即将迎来Harmoni-6 研究 ASCO 年会口头报告高光时刻之际，Summit Therapeutics 却被Harmoni-3研究的中期分析结果狠狠拉回现实。 5月1日，美股开盘后，Summit 股价一度暴跌超过 25%。导火索并非竞争对手的重磅数据，而是其自家明星管线——PD-1×VEGF 双特异性抗体 ivonescimab （依沃西单抗）——在全球 III 期 Harmoni-3 试验中的一次“不合时宜的失利”。 这并不是一次终局性失败，却足以让市场情绪急转直下，也更加凸显出头对头K药的OS究竟最终能否成阳性的重要性。 本期内容 01 Harmoni-3 中期分析：没达标 02 中期“失手”究竟意味着什么？ 03 总结与展望 【01 Harmoni-3 中期分析：没达标】 2026年4月30日，Summit Therapeutics公布一季度财报，根据 Summit 披露，Harmoni-3 试验中新加入的一次 中期 PFS 分析显示：鳞状非小细胞肺癌（sqNSCLC）队列未能达到统计学显著性。 来源：https://www.smmttx.com/ 需要强调的是三个关键信息： 第一，这是一次新增的中期分析。该分析并非原始设计的一部分，而是在 2025 年 2 月才临时加入，主要目的是探索是否存在提前申报的可能性。 第二，试验并未被叫停。独立数据监查委员会（IDMC）建议试验继续推进，并维持双盲状态，说明并未观察到明显的安全性或疗效风险信号。 第三，统计学门槛极高。Summit 在公告中明确指出，该中期分析消耗的 α 值极低（接近 0.001），显著性门槛明显高于最终 PFS 分析。 换句话说：“没过线” ≠ “没效果”，但也确实低于市场的心理预期。 如果只是一次中期分析未达标，本不至于引发如此剧烈的股价波动。真正的问题在于：Harmoni-3 承载的预期太高了。 1. 这是 ivonescimab 最关键的全球注册性试验 Harmoni-3 是一项全球多中心 III 期研究，对标的是 Keytruda + 化疗 这一绝对王者组合。一旦成功，其意义远超“又一个 PD-1 联合方案”，而是： 全球首个在一线 NSCLC 中正面挑战 Keytruda 的 PD-1×VEGF 双抗 为中国双抗走向全球提供关键临床背书 2. 中国数据“很惊艳” ivonescimab 在中国由康方生物开发，其早期临床战绩堪称惊艳： Harmoni-2：在 PD-L1 阳性 NSCLC 中，单药 PFS 相比 Keytruda 提升 49% Harmoni-6：在鳞状 NSCLC 中，联合化疗 PFS 较替雷利珠单抗 + 化疗提升 40% 在这样的背景下，资本市场早已默认一个前提：全球试验的数据即使有所下降，也不该降低得太多。 02 中期“失手”究竟意味着什么？ 由于 Summit 尚未披露具体统计方案和事件数，所有解读都只能是推演。但从分析师观点来看，核心分歧集中在两个可能性上。 可能性一：事件数不够，而非疗效不足 花旗分析师认为，PFS 事件累计数量可能低于预期，是导致统计学不显著的主要原因。在 α 值极度受限的情况下，即便存在真实疗效，也可能“算不出来”。 如果属实，那么问题更多是时间和设计层面的，而非药物本身。 可能性二：全球人群疗效确实“打折” 分析师推测，Harmoni-3 中 ivonescimab 的 PFS 效应量，可能比 Harmoni-6 低约 10 个百分点。 Harmoni-3 的这次中期分析，恰好发生在一个极其微妙的时间点。 Harmoni-6 的OS数据，即将以 ASCO plenary session 的最高规格公布。 这一安排本身，就是 ASCO 学术委员会给出的强烈信号。 ivonescimab + 化疗在 Harmoni-6 中带来的 OS 获益可能 ≥28%。如果这一判断成立，那么： 中国数据的“成色”将再次得到验证 Harmoni-3 的中期失利，可能被重新解读并被市场认可。反之，如果 OS 表现不及预期，那么市场将不得不重新评估：PD-1×VEGF 双抗，在全球人群中究竟还能否颠覆现有的标注疗法。 03 总结与展望 ivonescimab 的这次中期波折，本质上并不是一次失败，而是一次预期修正。 它提醒市场三件事： 中国临床数据不等于全球确定性 中期分析既是机会，也是风险 真正决定命运的，永远是 OS ASCO 即将开幕，Harmoni-6 的 OS 数据将站上全球肿瘤学舞台的中心。 到那一刻，PD-1×VEGF 双抗究竟是下一代基石疗法，还是阶段性高光故事，答案才会真正浮出水面。 新增科普账号，用更通俗的语言讲透临床知识，欢迎关注。 ★

Summit Therapeutics’ shares plunged more than 25% on the news in early trading Friday morning. A surprise interim trial miss in ivonescimab’s closely watched Harmoni-3 trial has sent Summit Therapeutics’ shares tumbling, casting a shadow over the company’s momentum as the star PD-1xVEGF bispecific heads into the ASCO annual meeting with a prestigious spot on the plenary session.The squamous cohort of Harmoni-3 has apparently missed statistical significance on progression-free survival (PFS) in a recently added interim analysis. Summit said Thursday an independent data monitoring committee recommended the study continue as planned and remain double-blinded.The trial is evaluating ivonescimab combined with chemotherapy against Merck & Co.’s Keytruda plus chemo for first-line treatment of metastatic non-small cell lung cancer. Summit’s shares plunged more than 25% on the news in early trading Friday morning. Analysts were broadly surprised and scrambled to figure out what could have happened in the black box. The market’s negative reaction is reasonable, Leerink Partners analysts wrote in a May 1 note to clients. The global Harmoni-3 trial is so important that Summit has tweaked its design at least twice: first to separate squamous and nonsquamous patients into two cohorts, and second, announced in February, to add a new interim analysis for PFS  in the squamous group in the second quarter.At the time, Summit framed the addition as an opportunity to speak with health authorities about a potential earlier submission, while the trial continues toward its final PFS and interim overall survival readouts, which the company still expects in the second half of 2026.Missing statistical significance at the interim analysis isn’t the end of the world.“To achieve statistical significance, there was a meaningfully higher bar than the upcoming planned final PFS analysis based on the minimal alpha spent on the interim analysis,” Summit said in its April 30 press release.But it’s still a major disappointment for investors. Harmoni-2 and Harmoni-6, two Chinese first-line NSCLC trials run by ivonescimab’s original developer, Akeso, both met their PFS endpoints at interim analyses. The first study showed ivonescimab monotherapy beat Keytruda by 49% on PFS in PD-L1-positive NSCLC. The second linked ivonescimab plus chemotherapy to a 40% PFS advantage over BeOne Medicines’ Tevimbra plus chemotherapy in squamous NSCLC.Analysts tried to crunch the numbers, but without knowing the exact statistical plan, any analysis so far is guesswork. “With likely minimal (~0.001) alpha spent on the interim, the bar was indeed high and most of the alpha is preserved for the final, we believe supporting eventual success,” Citi analysts wrote in a Thursday note.Citi analysts suspected the total number of PFS events accrued was lower than expected, causing the miss on statistical significance. But they couldn’t rule out that the magnitude of PFS improvement was simply weak.In Leerink’s base-case scenario, missing statistical significance suggests the PFS effect size is about 10 percentage points lower than that seen in Harmoni-6. But the team cautioned that “considerable uncertainty remains,” citing multiple unknowns, most crucially Summit’s statistical design.Harmoni-3’s latest PFS miss comes as an overall survival update from Harmoni-6 is set for a plenary session at the American Society of Clinical Oncology annual meeting, which kicks off later this month in Chicago.The result’s plenary placement excited investors. In an April 21 note, Leerink analysts said ivonescimab combined with chemotherapy likely drove a strong overall survival benefit, with at least a 28% improvement over Tevimbra plus chemotherapy.Analysts at both Leerink and Evercore ISI suggested that the stakes are now even higher for the Harmoni-6 readout. “[A] degradation in PFS benefit from the Chinese to global trial would make the combination a less compelling option,” Leerink wrote in a Friday note.“With investors expecting a degradation in benefit from the Chinese to global studies, the bar for excitement is higher,” the team added for the comparison between Harmoni-3 and -6.Similarly, an Evercore team wrote in a Thursday note that, “If the deterioration isn’t as dramatic as previously thought, that could be the saving grace until we get H-3 final PFS & interim OS in 2H26.”